A Canadian Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Tresiba (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus CAN-TREAT (CANadian TREsiba AudiT)
Phase of Trial: Phase IV
Latest Information Update: 24 Jan 2019
At a glance
- Drugs Insulin degludec (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CAN-TREAT
- Sponsors Novo Nordisk
- 18 Dec 2018 Planned End Date changed from 18 Jan 2019 to 15 Mar 2019.
- 28 Nov 2018 Status changed from not yet recruiting to recruiting.
- 05 Oct 2018 Planned initiation date changed from 14 Sep 2018 to 12 Oct 2018.